English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Phenylalanine effects on brain function in adult phenylketonuria

Pilotto, A., Zipser, E., Leks, E., Haas, D., Gramer, G., Freisinger, P., et al. (2020). Phenylalanine effects on brain function in adult phenylketonuria. Neurology, Epub ahead. doi:10.1212/WNL.0000000000011088.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0007-4DA9-5 Version Permalink: http://hdl.handle.net/21.11116/0000-0007-4DAE-0
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Pilotto, A, Author
Zipser, EM, Author
Leks, E1, 2, Author              
Haas, D, Author
Gramer, G, Author
Freisinger, P, Author
Schaeffer, E, Author
Liepelt-Scarfone, I, Author
Brockmann, K, Author
Maetzler, W, Author
Schulte, C, Author
Deuschle, C, Author
Hauser, AK, Author
Hoffmann, GF, Author
Scheffler, K1, 2, Author              
van Spronsen, FJ, Author
Padovani, A, Author
Trefz, F, Author
Berg, D, Author
Affiliations:
1Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497794              
2Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497796              

Content

show
hide
Free keywords: -
 Abstract: Objective To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric symptoms in adult phenylketonuria patients. Methods In this prospective cross-sectional study, early-treated phenylketonuria patients older than 30 years and age and sex-matched controls were included. Extensive neurologic evaluation, neuropsychological and behavioral testing, sensory and motor evoked potentials, and MRI were performed. CSF concentrations of neurodegenerative markers were in addition evaluated in a subset of 10 patients. Results Nineteen phenylketonuria patients (median age 41 years) with different phenylalanine levels (median 873 μmol/L) entered the study. They showed higher prevalence of neurologic symptoms, cognitive and behavioral abnormalities, autonomic dysfunction, alterations in neurophysiologic measures and atrophy in putamen and right thalamus compared to controls. In CSF, Phenylketonuria patients exhibited higher Aβ1-42 (p = 0.003), T-Tau (p < 0.001) and P-Tau (p = 0.032) levels compared to controls. Plasma phenylalanine levels highly correlated with the number of failed neuropsychological tests (r = 0.64, p = 0.003), neuropsychiatric symptoms (r = 0.73, p < 001) motor evoked potential latency (r = 0.48, p = 0.030) and parietal lobe atrophy. Conclusions Our study provides strong evidence for a correlation between phenylalanine levels and clinical, neuropsychological, neurophysiologic, biochemical and imaging alterations in adult phenylketonuria patients.

Details

show
hide
Language(s):
 Dates: 2020-10
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1212/WNL.0000000000011088
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Neurology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Cleveland, Ohio [etc.] : Advanstar Communications [etc.]
Pages: - Volume / Issue: Epub ahead Sequence Number: - Start / End Page: - Identifier: ISSN: 0028-3878
CoNE: https://pure.mpg.de/cone/journals/resource/954925246073